CONMED Corporation 2023 Form 10-K Summary
Business Context and Reporting Period
CONMED is a global medical technology company providing surgical devices and equipment for orthopedic, general surgery, gynecology, thoracic surgery and gastroenterology procedures. The filing covers the fiscal year ended December 31, 2023; it is an annual report rather than a standalone fourth-quarter filing. The company operated as a single reportable segment, with 43% of sales from orthopedic surgery and 57% from general surgery.
- Approximately 4,000 employees and products sold in more than 100 countries.
- International sales represented approximately 44% of consolidated net sales; 32% were denominated in local currencies.
- Approximately 83% of revenue came from single-use products, which management views as recurring.
Financial Performance and Key Metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net sales | $1,244.7 million | $1,045.5 million | +19.1% |
| Gross profit | $676.2 million | $571.2 million | +18.4% |
| Gross margin | 54.3% | 54.6% | -0.3 percentage points |
| Income from operations | $120.6 million | $70.1 million | +72.2% |
| Operating margin | 9.7% | 6.7% | +3.0 percentage points |
| Net income (loss) | $64.5 million | $(80.6) million | Returned to profitability |
| Diluted EPS | $2.04 | $(2.68) | Improved |
| Cash flow from operations | $125.3 million | $33.4 million | +275.8% |
- Orthopedic surgery sales increased 15.5% to $533.1 million; general surgery sales increased 21.9% to $711.6 million.
- Constant-currency sales growth was 20.9%, compared with reported growth of 19.1%; foreign exchange reduced sales by approximately $16.1 million.
- Single-use product sales increased 18.7% to $1,038.5 million; capital product sales increased 20.9% to $206.2 million.
- Selling and administrative expense declined to 40.4% of sales from 43.4%, while research and development expense increased to $52.6 million from $47.2 million.
- Interest expense increased to $39.8 million from $28.9 million, primarily because of higher variable borrowing rates and the full-year impact of the 2.250% convertible notes.
- Cash and cash equivalents were $24.3 million at year-end, including approximately $19.7 million held by foreign subsidiaries. Net working capital was $304.9 million.
Material Changes Versus the Prior Comparable Period
- Revenue growth benefited from the In2Bones and Biorez product lines acquired in 2022, growth in AirSeal and Buffalo Filter products, and substantial improvement in the warehouse management system that had caused shipping delays in late 2022.
- Operating results improved materially as 2022 included $112.0 million of other expense, principally the conversion premium and related costs from repurchasing and extinguishing $275.0 million of 2.625% convertible notes. No comparable other expense was recorded in 2023.
- Gross margin declined modestly because of inflation and higher raw-material and production costs, partly offset by higher volume and favorable mix. In2Bones inventory fair-value step-up amortization was $8.6 million in 2023 versus $4.5 million in 2022.
- Operating cash flow improved as earnings increased, acquisition integration costs declined, and inventory levels were moderated. Investing cash usage fell to $20.0 million from $249.5 million because 2022 included payments for the In2Bones and Biorez acquisitions.
- Debt declined to $973.8 million from $1,054.8 million, while financing activities used $110.4 million in 2023 compared with providing $225.0 million in 2022.
Liquidity, Debt and Capital Allocation
- Total debt was $986.6 million on a contractual basis, or approximately 54% of total capitalization. The balance sheet reported $973.8 million after deferred issuance costs and included $785.4 million of 2.250% convertible notes due 2027.
- The term loan balance was $114.6 million and revolving credit borrowings were $2.0 million at December 31, 2023. Available revolving capacity was $581.4 million, with approximately $1.6 million reserved for letters of credit.
- The company was in compliance with its credit agreement covenants at year-end. The credit facilities mature in 2026, while the 2.250% convertible notes mature in 2027.
- In February 2024, CONMED repaid the $70.0 million outstanding 2.625% convertible notes using borrowings under its revolving credit facility.
- Contractual obligations totaled $1.35 billion, including $986.6 million of long-term debt, $170.1 million of contingent consideration, $166.8 million of purchase obligations and $23.7 million of lease obligations.
- The company paid a quarterly dividend of $0.20 per share and had $37.4 million remaining under its $200 million share repurchase authorization. No shares were repurchased under the program during 2023.
Outlook, Management Commentary, Risks and Unusual Items
- Management expects inflationary pressures and supply-chain challenges to continue affecting manufacturing and operating costs in 2024 and expects higher capital spending than in 2023.
- Management believes operating cash flow, cash on hand and available borrowing capacity will be adequate for expected working capital, debt service, capital expenditures, dividends and repurchases in the foreseeable future; management also notes that additional cost reductions or debt refinancing may be required.
- Contingent consideration liabilities related to the 2022 acquisitions totaled $170.1 million at year-end, including $41.4 million for In2Bones and $128.8 million for Biorez. Payments are dependent on revenue and performance milestones and are based on significant Level 3 valuation assumptions.
- CONMED voluntarily informed the U.S. Department of Justice in December 2023 of potential issues involving certain royalty payments to design surgeons and is cooperating with the review. The filing states that no reserve was recorded because a loss was not considered probable or estimable.
- Product, regulatory, healthcare reimbursement, competitive pricing, raw-material availability, EtO sterilization capacity, foreign-exchange, cybersecurity and acquisition-integration risks could materially affect results.
- Approximately 29% of revenue is associated with products sterilized by third parties using ethylene oxide. The company had secured capacity as of the filing date but identified potential future restrictions as a risk.
- The company disclosed Georgia litigation involving alleged EtO exposure, related insurance coverage litigation and an indemnification notice from a contract sterilizer. Potential losses were generally not estimable and no material reserve was recorded.
- The company reported no cybersecurity incident that materially affected, or was reasonably likely to materially affect, its business, results of operations or financial condition during 2023 or through the filing date.
- Goodwill and indefinite-lived intangible asset testing performed in the fourth quarter of 2023 indicated no impairment.
Important Facts for Investors to Verify
- Whether 2024 revenue growth from In2Bones, Biorez, AirSeal, Buffalo Filter and other products can offset inflation, foreign-exchange pressure and potential healthcare purchasing constraints.
- The timing and amount of contingent consideration payments and the sensitivity of the $170.1 million liability to acquired-business performance and valuation assumptions.
- Debt repayment capacity, variable-rate exposure and refinancing requirements as the 2026 credit facilities and 2027 convertible notes approach maturity.
- The outcome and potential financial impact of the DOJ review concerning royalty payments, Georgia EtO-related litigation and the Italian medical device tax dispute.
- Availability of third-party EtO sterilization capacity and the company’s ability to manage supplier concentration and other supply-chain disruptions.
- Whether the stated increase in 2024 capital spending and continued dividends and share repurchases remain consistent with cash generation and leverage objectives.